Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial ; volume:28 ; number:12 ; day:8 ; month:12 ; year:2022 ; pages:2573-2583 ; date:12.2022
Nature medicine ; 28, Heft 12 (8.12.2022), 2573-2583, 12.2022
- Urheber
-
Røssevold, Andreas Hagen
Andresen, Nikolai Kragøe
Bjerre, Christina Annette
Gilje, Bjørnar
Jakobsen, Erik Hugger
Raj, Sunil Xavier
Falk, Ragnhild Sørum
Russnes, Hege Giercksky
Jahr, Thea
Mathiesen, Randi Ruud
Lømo, Jon
Garred, Øystein
Chauhan, Sudhir Kumar
Lereim, Ragnhild Reehorst
Dunn, Claire
Naume, Bjørn
Kyte, Jon Amund
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-022-02126-1
- URN
-
urn:nbn:de:101:1-2023120423292309061419
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Røssevold, Andreas Hagen
- Andresen, Nikolai Kragøe
- Bjerre, Christina Annette
- Gilje, Bjørnar
- Jakobsen, Erik Hugger
- Raj, Sunil Xavier
- Falk, Ragnhild Sørum
- Russnes, Hege Giercksky
- Jahr, Thea
- Mathiesen, Randi Ruud
- Lømo, Jon
- Garred, Øystein
- Chauhan, Sudhir Kumar
- Lereim, Ragnhild Reehorst
- Dunn, Claire
- Naume, Bjørn
- Kyte, Jon Amund
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Anthracycline Chemotherapy and Cardiotoxicity
FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
Metabolic Aspects of Anthracycline Cardiotoxicity
Cardioprotection strategies for anthracycline cardiotoxicity
Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Novel Anthracycline Utorubicin for Cancer Therapy
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Anthracycline Chemotherapy and Cardiotoxicity
FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
Metabolic Aspects of Anthracycline Cardiotoxicity
Cardioprotection strategies for anthracycline cardiotoxicity
Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Novel Anthracycline Utorubicin for Cancer Therapy
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Anthracycline Chemotherapy and Cardiotoxicity
FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
Metabolic Aspects of Anthracycline Cardiotoxicity
Cardioprotection strategies for anthracycline cardiotoxicity
Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction
Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study